Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leymovir Versus Valganciclovir in Prevention of CMV Infection and Disease in Chinese Kidney Transplant Recipients
NCT07266467Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of letermovir in cytomegalovirus infection (CMV), cytomegalovirus disease (CMV), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Started May 2025; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on NCT07266467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266467.